Clovis Oncology Company Profile (NASDAQ:CLVS)

About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology logoClovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CLVS
  • CUSIP: 18946410
  • Web:
  • Market Cap: $2.46 billion
  • Outstanding Shares: 44,772,000
Average Prices:
  • 50 Day Moving Avg: $53.68
  • 200 Day Moving Avg: $52.55
  • 52 Week Range: $11.57 - $74.94
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.87
  • P/E Growth: -0.35
Sales & Book Value:
  • Annual Revenue: $7.12 million
  • Price / Sales: 346.10
  • Book Value: $3.89 per share
  • Price / Book: 14.15
  • EBIDTA: ($262,070,000.00)
  • Return on Equity: -178.58%
  • Return on Assets: -56.45%
  • Debt-to-Equity Ratio: 4.92%
  • Current Ratio: 5.61%
  • Quick Ratio: 5.61%
  • Average Volume: 1.76 million shs.
  • Beta: 1.97
  • Short Ratio: 3.65

Frequently Asked Questions for Clovis Oncology (NASDAQ:CLVS)

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology Inc (NASDAQ:CLVS) issued its quarterly earnings results on Wednesday, May, 3rd. The company reported ($1.33) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.43) by $0.10. The company had revenue of $7.05 million for the quarter, compared to analyst estimates of $6.04 million. View Clovis Oncology's Earnings History.

Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2017?

13 brokerages have issued 12-month target prices for Clovis Oncology's shares. Their forecasts range from $23.00 to $86.00. On average, they anticipate Clovis Oncology's share price to reach $61.17 in the next twelve months. View Analyst Ratings for Clovis Oncology.

What are analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:

  • 1. Goldman Sachs Group Inc analysts commented, "AZN (covered by Keyur Parekh) presented data from a Ph3 SOLO-2 maintenance ovarian cancer trial of Lynparza (PARP inhibitor) on March 14 at the SGO conference, which we believe has implications for CLVS (lead marketed drug Rubraca is also a PARP). CLVS, AZN and TSRO (not covered) all have PARP inhibitors that they are evaluating for use in the maintenance treatment of ovarian cancer." (3/15/2017)
  • 2. According to Zacks Investment Research, "Clovis got a huge boost with the FDA granting accelerated approval to its advanced ovarian cancer treatment, Rubraca. It is not only the first approved product in Clovis’ portfolio, but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for PARP inhibitors. Successful commercialization will significantly boost Clovis’ top line, going forward. Rubraca is also under review in the EU for a comparable ovarian cancer indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Meanwhile, Clovis is looking to expand Rubraca’s label into additional indication like prostrate, breast and pancreatic cancers, among others. Also, shares of Clovis outperformed the industry in the past one year. Estimates have been stable ahead of Q4 results. However, Clovis’ dependence on Rubraca alone for growth is a cause for concern." (2/8/2017)
  • 3. Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)
  • 4. JPMorgan Chase & Co. analysts commented, "CLVS’ 2Q report this afternoon was fairly uneventful, though the co did note that rucaparib’s full NDA dataset had been accepted for presentation at ESMO (Oct 7- 11, Copenhagen), and that ARIEL3 data (rucap in maintenance) is now expected in 4Q17 following release of a similar data set from TSRO (though CLVS has no knowledge of the event rate in ARIEL3). While we do see potential value for rucap, we think it’s hard to differentiate between the PARPs at this stage, and we are maintaining our Neutral rating." (8/9/2016)

Who are some of Clovis Oncology's key competitors?

Who owns Clovis Oncology stock?

Clovis Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LLC (8.70%), Vanguard Group Inc. (7.33%), State Street Corp (4.16%), FMR LLC (4.06%), Wellington Management Group LLP (2.97%) and Boxer Capital LLC (2.23%). Company insiders that own Clovis Oncology stock include Erle T Mast, Gillian C Ivers-Read and Lindsey Rolfe. View Institutional Ownership Trends for Clovis Oncology.

Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?

Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY, Redmile Group LLC, State Street Corp, Goldman Sachs Group Inc., Blue Jay Capital Management LLC, Morgan Stanley, Jennison Associates LLC and UBS Group AG. View Insider Buying and Selling for Clovis Oncology.

Who bought Clovis Oncology stock? Who is buying Clovis Oncology stock?

Clovis Oncology's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Wellington Management Group LLP, Alliancebernstein L.P., Vanguard Group Inc., Emerald Advisers Inc. PA, Bogle Investment Management L P DE, Boxer Capital LLC and Cibc World Markets Corp. View Insider Buying and Selling for Clovis Oncology.

How do I buy Clovis Oncology stock?

Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Clovis Oncology stock cost?

One share of Clovis Oncology stock can currently be purchased for approximately $55.04.

Analyst Ratings

Consensus Ratings for Clovis Oncology (NASDAQ:CLVS) (?)
Ratings Breakdown: 2 Sell Ratings, 4 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $61.17 (11.13% upside)

Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017ValuEngineDowngradeHold -> SellMediumView Rating Details
5/17/2017Bank of America CorpReiterated RatingBuy$75.00MediumView Rating Details
5/17/2017JPMorgan Chase & Co.UpgradeNeutral -> Overweight$72.00HighView Rating Details
5/2/2017Morgan StanleyReiterated RatingOverweight$79.00HighView Rating Details
4/18/2017Credit Suisse Group AGReiterated RatingOutperform$74.00LowView Rating Details
3/28/2017Piper Jaffray CompaniesSet Price TargetBuy$77.00LowView Rating Details
3/16/2017Chardan CapitalReiterated RatingSell$36.00LowView Rating Details
3/15/2017Goldman Sachs Group IncBoost Price TargetNeutral$44.00 -> $75.00HighView Rating Details
1/23/2017Stifel NicolausBoost Price TargetBuy$52.00 -> $86.00N/AView Rating Details
12/21/2016WallachBeth CapitalBoost Price TargetHold$22.00 -> $49.00N/AView Rating Details
12/20/2016Janney Montgomery ScottSet Price TargetHold$38.00N/AView Rating Details
9/23/2016SunTrust Banks, Inc.Boost Price TargetBuy$38.00 -> $50.00N/AView Rating Details
8/24/2016MizuhoBoost Price TargetNeutral$15.00 -> $23.00N/AView Rating Details
3/28/2016Leerink SwannBoost Price TargetOutperform$104.00 -> $110.00N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Clovis Oncology (NASDAQ:CLVS)
Earnings by Quarter for Clovis Oncology (NASDAQ:CLVS)
Earnings History by Quarter for Clovis Oncology (NASDAQ:CLVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($1.43)($1.33)$6.04 million$7.05 millionViewListenView Earnings Details
2/22/2017Q416($1.65)($1.83)$0.08 millionViewListenView Earnings Details
11/3/2016Q316($1.95)($1.70)ViewListenView Earnings Details
8/8/2016Q216($2.13)($2.07)ViewListenView Earnings Details
5/5/2016Q116($2.39)($2.17)ViewListenView Earnings Details
2/25/2016Q415($2.39)($2.23)ViewListenView Earnings Details
11/5/2015Q315($2.07)($2.62)ViewListenView Earnings Details
8/6/2015Q215($2.11)($2.10)$1.17 millionViewListenView Earnings Details
5/6/2015Q115($1.78)($1.86)$13.60 millionViewListenView Earnings Details
2/25/2015Q414($1.41)($1.62)ViewListenView Earnings Details
11/6/2014Q314($1.03)($1.17)ViewListenView Earnings Details
8/7/2014Q214($0.93)($1.03)$13.60 millionViewListenView Earnings Details
5/8/2014Q114($0.85)($0.91)$13.60 millionViewListenView Earnings Details
2/27/2014Q4($0.78)($0.92)ViewListenView Earnings Details
10/31/2013Q313($0.68)($0.68)ViewListenView Earnings Details
8/1/2013Q2 2013($0.65)($0.72)ViewListenView Earnings Details
5/7/2013Q1 2013($0.60)($0.60)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)
2017 EPS Consensus Estimate: ($5.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.53)($1.53)($1.53)
Q2 20171($1.21)($1.21)($1.21)
Q3 20171($1.13)($1.13)($1.13)
Q4 20171($1.22)($1.22)($1.22)
(Data provided by Zacks Investment Research)


Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Clovis Oncology (NASDAQ:CLVS)
Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 88.48%
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Gillian C Ivers-ReadInsiderSell3,000$47.39$142,170.00View SEC Filing  
4/17/2017Gillian C Ivers-ReadInsiderSell3,000$56.02$168,060.00View SEC Filing  
3/15/2017Gillian C Ivers-ReadInsiderSell3,000$66.99$200,970.00View SEC Filing  
11/2/2015Erle T. MastCFOSell3,000$105.56$316,680.00View SEC Filing  
10/28/2015Lindsey RolfeinsiderSell4,000$98.02$392,080.00View SEC Filing  
10/15/2015Gillian C Ivers-ReadInsiderSell3,000$91.91$275,730.00View SEC Filing  
10/5/2015Lindsey RolfeinsiderSell4,000$93.04$372,160.00View SEC Filing  
10/1/2015Erle T. MastCFOSell3,000$90.22$270,660.00View SEC Filing  
9/18/2015Gillian C Ivers-ReadInsiderSell3,000$112.56$337,680.00View SEC Filing  
9/1/2015Erle T. MastCFOSell3,000$79.51$238,530.00View SEC Filing  
7/1/2015Erle T MastCFOSell3,000$85.70$257,100.00View SEC Filing  
6/1/2015Erle T MastCFOSell3,000$88.78$266,340.00View SEC Filing  
5/15/2015M James BarrettDirectorSell2,424$92.43$224,050.32View SEC Filing  
4/1/2015Erle T MastCFOSell3,000$71.25$213,750.00View SEC Filing  
3/9/2015Erle T MastCFOSell9,000$78.84$709,560.00View SEC Filing  
3/5/2015James C BlairDirectorSell8,528$77.70$662,625.60View SEC Filing  
1/16/2015Steven L HoerterInsiderSell10,000$67.00$670,000.00View SEC Filing  
12/11/2013Erle MastCFOSell50,000$52.78$2,639,000.00View SEC Filing  
12/5/2013Thorlef SpickschenDirectorSell9,000$56.10$504,900.00View SEC Filing  
6/5/2013Andrew R AllenInsiderSell22,594$68.54$1,548,592.76View SEC Filing  
6/4/2013M James BarrettDirectorSell2,483$70.80$175,796.40View SEC Filing  
6/4/2013Parters Vii L P DomainMajor ShareholderSell159,192$64.58$10,280,619.36View SEC Filing  
6/4/2013Steven L HoerterInsiderSell10,000$73.06$730,600.00View SEC Filing  
3/6/2013Parters Vii L P DomainMajor ShareholderSell250,000$24.59$6,147,500.00View SEC Filing  
8/16/2012Edward J MckinleyDirectorBuy9,701$15.50$150,365.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Clovis Oncology (NASDAQ:CLVS)
Latest Headlines for Clovis Oncology (NASDAQ:CLVS)
DateHeadline logo Analysts Expect Clovis Oncology Inc (CLVS) Will Announce Earnings of -$1.24 Per Share - May 25 at 12:24 PM logoClovis Oncology (CLVS) Announces Presentations at 2017 ASCO - - May 23 at 12:47 PM logoClovis Oncology Announces Presentations at 2017 ASCO Annual Meeting - May 23 at 12:47 PM logoClovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain - May 22 at 12:34 PM logoClovis Oncology Inc (CLVS) Lowered to "Sell" at ValuEngine - May 19 at 4:04 PM logoUPDATE: JPMorgan Upgrades Clovis Oncology (CLVS) to Overweight; 'Pullback Creates Enticing Risk/Reward ... - - May 18 at 11:09 AM logoClovis Oncology Inc (CLVS) Upgraded at JPMorgan Chase & Co. - May 17 at 11:38 PM logoClovis Oncology (CLVS): Management Dinner Highlights - BofA - - May 17 at 4:25 PM logoBuy the dip in Clovis Oncology - JPMorgan - Seeking Alpha - May 17 at 4:25 PM logoBank of America Corp Reaffirms Buy Rating for Clovis Oncology Inc (CLVS) - May 17 at 12:16 PM logoClovis Oncology Inc (CLVS) Receives Average Recommendation of "Buy" from Brokerages - May 16 at 10:31 AM logoInsider Selling: Clovis Oncology Inc (CLVS) Insider Sells 3,000 Shares of Stock - May 15 at 7:50 PM logoSunTrust Banks Weighs in on Clovis Oncology Inc's Q2 2017 Earnings (CLVS) - May 8 at 8:15 AM logoClovis Oncology Inc (CLVS) Posts Earnings Results, Beats Expectations By $0.10 EPS - May 4 at 11:08 PM logo$10.87 Million in Sales Expected for Clovis Oncology Inc (CLVS) This Quarter - May 4 at 2:20 PM logoEdited Transcript of CLVS earnings conference call or presentation 3-May-17 8:30pm GMT - May 4 at 5:38 AM logoClovis Oncology (CLVS) Receiving Somewhat Positive Media Coverage, Analysis Finds - May 3 at 10:06 PM logoClovis reports 1Q loss - May 3 at 5:45 PM logoClovis Oncology beats by $0.15, beats on revenue - May 3 at 4:44 PM logoNotable Wednesday Option Activity: CLVS, PRU, LITE - May 3 at 4:21 PM logoClovis Oncology Announces First Quarter 2017 Operating Results - May 3 at 4:21 PM logoMorgan Stanley Reaffirms "Overweight" Rating for Clovis Oncology Inc (CLVS) - May 2 at 7:44 PM logo Brokerages Anticipate Clovis Oncology Inc (CLVS) to Announce -$1.43 Earnings Per Share - May 2 at 9:08 AM logoClovis Oncology (CLVS) Receiving Somewhat Positive Press Coverage, AlphaOne Reports - April 28 at 5:33 PM logoMyriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved ... - April 27 at 10:23 AM logoClovis Oncology (CLVS) Receiving Somewhat Favorable Media Coverage, Report Shows - April 25 at 4:55 PM logoTesaro Inc Bulls Need a Reality Check - April 25 at 4:09 PM logoClovis Oncology (CLVS) Getting Somewhat Positive Media Coverage, Study Finds - April 21 at 5:06 PM logoClovis Oncology Inc (CLVS) Receives Consensus Rating of "Buy" from Brokerages - April 21 at 11:51 AM logoTesaro’s Zejula Flops as H&S Pattern Emerges (TSRO, CLVS) - April 21 at 9:25 AM logoTesaro’s Zejula Flops as H&S Pattern Emerges - April 21 at 9:25 AM logoTesaro's Path to a Billion-Dollar Blockbuster Begins With Pricing - April 21 at 9:25 AM logoClovis Oncology to Announce First Quarter 2017 Financial Results and Host Webcast Conference Call on May 3 - April 20 at 4:29 PM logoTesaro Dives On 'Sticker Shock' For $177,000 Drug - April 20 at 4:29 PM logoMorgan Stanley is bullish on gambling, bearish on jelly - April 19 at 4:20 PM logoSomewhat Positive Media Coverage Likely to Affect Clovis Oncology (CLVS) Share Price - April 18 at 2:20 PM logoClovis Oncology Inc (CLVS) Given Outperform Rating at Credit Suisse Group AG - April 18 at 2:08 PM logoGillian C. Ivers-Read Sells 3,000 Shares of Clovis Oncology Inc (CLVS) Stock - April 17 at 11:05 PM logoClovis Oncology (CLVS) Earning Somewhat Favorable News Coverage, Analysis Finds - April 15 at 12:56 PM logo$6.04 Million in Sales Expected for Clovis Oncology Inc (CLVS) This Quarter - April 13 at 1:46 PM logoWhy Clovis Oncology's Stock Edged Higher in March - April 7 at 5:04 PM logoResearch Reports Initiation on Biotech Stocks -- Sarepta Therapeutics, Galena Biopharma, Anthera Pharma, and Clovis Oncology - April 7 at 9:02 AM logoClovis Oncology Inc (CLVS) PT Set at $77.00 by Piper Jaffray Companies - April 3 at 9:23 AM logoClovis Oncology (CLVS) Says Rucaparib Preclinical Data to be Presentations at AACR - March 29 at 12:15 PM logoClovis Oncology Inc (CLVS) Given a $77.00 Price Target at Piper Jaffray Companies - March 28 at 10:33 PM logoClovis Oncology Announces Data Presentations at AACR Annual Meeting 2017 - March 28 at 9:07 PM logoWhy Is Clovis (CLVS) Up 18.8% Since the Last Earnings Report? - March 28 at 12:35 PM logoBiotech M&A Trade Hits a Snag - March 28 at 12:35 PM logoTesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer - March 27 at 4:17 PM logoClovis Oncology Inc (CLVS) Receives Average Recommendation of "Buy" from Analysts - March 27 at 12:44 PM



Clovis Oncology (CLVS) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff